Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thiodimethylsildenafil is an unapproved **small-molecule phosphodiesterase-5 inhibitor** that is structurally related to sildenafil and has been identified as an illicit adulterant in dietary supplements marketed for sexual enhancement. It is a dimethylated thio-derivative of sildenafil rather than a legitimate therapeutic candidate, and there is no evidence of bona fide pharmaceutical development, approved medical use, or recognized commercial manufacture. Its relevance is primarily analytical and regulatory: the compound is used as a reference standard for laboratory detection of adulterated supplements and represents a public health concern because undeclared PDE-5 inhibitor analogues may expose consumers to unpredictable pharmacology and safety risks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiodimethylsildenafil.